Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

17 results about "Pancreatic islet function" patented technology

Physiological activity and functions of the pancreatic islets as a whole or of any of its cells that provide for the secretion of insulin and other hormones.

Precise typing and dynamic treatment system for type 2 diabetes mellitus

The invention relates to the technical field of medical information processing, in particular to a type 2 diabetes precise typing and dynamic treatment system which comprises a clinical feature extraction module, a metabolism dynamic modeling module, a precise typing module, a treatment parameter generation module and a dynamic treatment output module. Wherein the clinical feature extraction module is used for collecting a multi-dimensional clinical data set of a patient for continuous 14 days; the metabolism dynamic modeling module is used for extracting blood glucose fluctuation characteristics and pancreas islet function compensation characteristics; the precise typing module is used for dividing metabolism-driven subtypes to which the patients belong through a clustering algorithm; the treatment parameter generation module is used for mapping a subtype-treatment rule base and outputting a matched personalized treatment parameter combination; and the dynamic treatment output module outputs a dynamic treatment scheme. According to the invention, through a dynamic treatment mechanism based on typing, linkage control of individual difference identification and real-time adjustment of the medication scheme of the type 2 diabetes patients is realized, and the accuracy and adaptability of treatment are improved.
Owner:AFFILIATED HOSPITAL OF JINHUA VOCATIONAL & TECHNICAL UNIVERSITY

Use of an ikk inhibitor for the preparation of a medicament for restoring pancreatic islet function

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.
Owner:ZHEJIANG UNIV

Application of SAFit2 in preparation of reagent for improving pancreas islet dysfunction

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.
Owner:TIANJIN FIRST CENT HOSPITAL

Traditional Chinese medicine ointment for improving pancreas islet function as well as preparation method and application of traditional Chinese medicine ointment

The invention discloses a traditional Chinese medicine ointment for improving pancreas islet function and a preparation method and application thereof. The traditional Chinese medicine ointment is prepared from ginseng, astragalus membranaceus, radix ophiopogonis, salvia miltiorrhiza, corn stigma, radix polygonati officinalis, radices trichosanthis, dandelion root, Chinese yam, poria cocos, radix puerariae, purslane, potentilla discolor, cyclocarya paliurus, folium mori, liquorice, momordica grosvenori, radix rehmanniae recen, coptis chinensis, chrysanthemum, honeysuckle, buckwheat, rhizoma anemarrhenae, cinnamon, bitter gourd, gynostemma pentaphyllum, cortex lycii radicis, rhizoma phragmitis and the like according to a specific weight part ratio. The invention further provides a preparation method of the traditional Chinese medicine ointment. The preparation method comprises the steps of soaking in water, decocting and extracting, filtering and concentrating, ointment collecting and the like. The traditional Chinese medicine ointment can remarkably reduce fasting blood glucose and postprandial blood glucose of diabetic model mice and improve abnormal glucose tolerance, and has a protection effect on pancreas islet tissues. The traditional Chinese medicine ointment can be used for preparing health care products for assisting in reducing blood sugar or pharmaceutical compositions for preventing and assisting in treating type 2 diabetes mellitus, and has the advantages of reasonable formula, exact curative effect, stable preparation process and the like.
Owner:康战

Use of pvrig as a target in the preparation of a product for diagnosing and predicting disease progression in type 1 diabetes

The application provides application of PVRIG as a target point in preparation of a type 1 diabetes diagnosis and disease progression prediction product. Specifically, PVRIG has different expressions on the surfaces of NK cells, CD16 positive NK cells and CD16 negative NK cells in honeymoon patients and non-honeymoon patients of type 1 diabetes, and PVRIG has different expressions on the surfaces of NK cells, CD16 positive NK cells and CD16 negative NK cells in patients with faster islet function failure and patients with slower islet function failure of type 1 diabetes, so that PVRIG is closely related to type 1 diabetes, can be used as a new target point of type 1 diabetes, and provides a new way for diagnosis and disease progression prediction of type 1 diabetes.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Pancreatic beta cell precursor cell transplantation chip for diabetes treatment

PendingCN121534087AMetabolism disorderPancreatic cellsPancreatic hormonePancreatic A Cells
The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.
Owner:安胜军

Traditional Chinese medicine herbal composition for preventing and treating diabetic complications and preparation method thereof

The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a traditional Chinese medicine herbal composition for preventing and treating diabetic complications and a preparation method thereof. The traditional Chinese medicine herbal composition is prepared from folium mori, radix astragali, radix rehmanniae, radix polygonati officinalis, radix ophiopogonis, rhizoma dioscoreae, poria cocos, radix puerariae, opuntia ficus-indica, inulin, rumex hanus, American ginseng and rhizoma curcumae longae. The traditional Chinese medicinal materials are combined to clean sugar scale micro-crystals in blood vessel microcirculation, improve the functions of liver and pancreas islet, regulate the blood sugar level and enhance the anti-oxidation and self-healing capability of a body, so that the blood sugar is stabilized; the occurrence of diabetic complications such as fundus retinopathy, neuropathy, hypertension, cerebral infarction, myocardial infarction, uremia and gangrene is prevented and controlled. Besides, the traditional Chinese medicine composition is a pure herbal traditional Chinese medicine formula, is high in safety and exact in curative effect, and has a wide application prospect in the field of prevention and treatment of diabetic complications.
Owner:BEIJING SUNSHINE FOUNDATION PHARMACEUTICAL TECHNOLOGY CO LTD

Application of methyl cellulose in suspension culture of pancreatic cell mass

The invention discloses an application of methyl cellulose in suspension culture of pancreatic cell masses. The invention also provides a method for suspension culture of a pancreatic cell mass, a pancreatic cell mass culture produced by the method, and a pharmaceutical composition and application of the pancreatic cell mass culture. The method provided by the invention comprises the step of carrying out suspension culture on pancreatic cell clusters in a culture medium containing methylcellulose, the number of the cell clusters cultured and harvested by the method is more, the average diameter of the cell clusters is better controlled, and the expression proportion of related markers is higher; the method has a good application prospect in preparation of regenerated pancreas islet tissues and treatment of diseases or symptoms related to pancreas islet function impairment.
Owner:ENDOCELL THERAPEUTICS INC +1

Use of agents to detect NETs in the assessment of early prognosis after islet transplantation

PendingCN122652043APhysiologyPancreatic islet transplantation
The application discloses application of a reagent for detecting NETs in evaluation of early prognosis after islet transplantation. The application verifies that early NETs increase after islet transplantation is related to transplantation prognosis and islet function through experiments. The application can stratify and evaluate early prognosis after islet transplantation in an extremely early stage after islet transplantation, and the earliest time is 2 hours after islet transplantation, and early prognosis after islet transplantation is judged based on changes in detection levels. The application discloses an important role of NETs in islet transplantation prognosis, provides a simple, reliable and quantifiable evaluation method, and has important clinical significance and social and economic benefits for improving the management level of islet transplantation patients, reducing early islet loss after islet transplantation and saving medical resources.
Owner:SHENZHEN PEOPLES HOSPITAL

Targeting prkar2b to enhance beta-islet function and survival for treatments of diabetes

A method to enhance beta-islet function and survival for treatments of diabetes by targeting PRKAR2B, and a method of preparing genetically modified human pluripotent stem cell (hPSC) in vitro, comprising providing hPSCs, with said modification comprising reducing or eliminating the expression or function of the gene products of the PRKAR2B gene in said hPSCs to be capable of differentiating in vitro to give rise to beta islets with enhanced function in glucose-stimulated insulin secretion and cell survival,are provided.
Owner:SHANGHAI VITALGEN BIOPHARMA CO LTD

A stem cell therapy for type 2 diabetes

PendingCN122140957AOrganic active ingredientsPeptide/protein ingredientsBeta-cell FunctionMicrovesicle
The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.
Owner:TEMSEL STEM CELL TECHNOLOGY (BEIJING) CO LTD

Application of GPR110 as therapeutic target of type 2 diabetes

PendingCN121951032AImprove metabolic abnormalitiesIncreased sensitivityMetabolism disorderMicrobiological testing/measurementLow insulinGPR110
The invention discloses an application of GPR110 as a therapeutic target of type 2 diabetes mellitus. The application discovers that the GPR110 gene is used as a therapeutic target of type 2 diabetes for the first time, and provides application of adenovirus-mediated GPR110 gene overexpression in preparation of drugs for treating type 2 diabetes. In an adult type 2 diabetes mouse model db / db, through caudal vein injection of adenovirus-mediated GPR110 overexpression, it is found that the type 2 diabetes related symptoms are significantly improved. The blood glucose level and the fasting blood glucose level are obviously reduced, and an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved. In addition, a decrease in serum insulin level prompts a reduction in pancreatic islet function burden. The results show that the adenovirus-mediated GPR110 overexpression can effectively improve the metabolic disorder of mice with type 2 diabetes mellitus, and a new intervention method and means are provided for the treatment of the type 2 diabetes mellitus.
Owner:SHANGHAI SIXTH PEOPLES HOSPITAL

Preparation method of umbilical cord mesenchymal stem cell exosome and application of umbilical cord mesenchymal stem cell exosome in treatment of diabetes

The invention discloses a GLP1 fusion protein with pancreas islet targeting, an exosome modified by the GLP1 fusion protein as well as a preparation method and application of the GLP1 fusion protein. The structure of the fusion protein is TP-linker-Lamp2b-linker-GLP1, the amino acid sequence of the pancreas islet targeting polypeptide TP is CPKTRRVY, and the pancreas islet targeting polypeptide TP can be specifically combined with pancreas islet beta cells; the amino acid sequence of the Linker is GSGSGSGSGS, so that the immunogenicity can be reduced, and the structural shielding can be avoided; the amino acid sequence of Lamp2b is as shown in SEQ ID NO.1, and exosome membrane anchoring can be realized; the amino acid sequence of the GLP1 mutant is HGEGTFPSDVSYLEGQAAKEFI AWLVKGR, and the half-life period of the GLP1 mutant is remarkably prolonged through A2G / T7P mutation. The invention also provides a preparation method of the fusion protein modified exosome. The preparation method comprises the steps of lentiviral vector construction, hUC-MSCs transduction and exosome extraction. In-vitro and in-vivo experiments prove that the modified exosome can target pancreas islet beta cells, efficiently exert the hypoglycemic effect of the GLP1 and remarkably improve the pancreas islet function, and a novel strategy which is high in targeting property, long-acting and efficient in delivery is provided for diabetes treatment.
Owner:GUANGDONG RUIDAN BIOTECHNOLOGY DEVELOPMENT CO LTD

Composition with sugar control effect, preparation method of composition and application of composition in food and health care products

The invention relates to the field of food health-care products, in particular to a composition with a sugar control effect, a preparation method of the composition and application of the composition to the food health-care products. Comprising the following components in parts by weight: 5-15 parts of a rhodiola rosea extract, 15-25 parts of prebiotics, 10-20 parts of a mulberry leaf extract, 20-40 parts of Chinese yam powder, 3-8 parts of vitamin B family, 1-5 parts of lipoic acid, 5-15 parts of anthocyanin and 5-15 parts of an adhesive. Through synergism of multiple components of the rhodiola rosea extract, the prebiotics, the mulberry leaf extract, the Chinese yam powder, the vitamin B family, the lipoic acid and the anthocyanin, natural plant extracts are used as main materials, and necessary synthetic nutrients are used as auxiliary materials, so that auxiliary control of blood sugar from three dimensions of inhibiting sugar absorption, regulating metabolism and protecting pancreas islet functions can be realized, and the effect of preventing and treating pancreas islet is achieved. In addition, by reducing oxidative stress and release of inflammatory factors, nerves and blood vessels can be effectively protected, and complications of diabetes mellitus can be prevented or delayed.
Owner:NINGBO OSAKI BIOTECH CO LTD

Pancreas islet organ simulating pancreas in vivo and construction method and application of pancreas islet organ

The invention specifically discloses a pancreas islet-like organ simulating an in-vivo pancreas and a construction method and application thereof, and relates to the technical field of organoid culture. According to the pancreas islet organ construction method, the technical cost is greatly reduced, and the obtained pancreas islet is high in functionality, small in intra-group difference, high in repeatability, small in batch difference and simple to operate. The method not only can be applied to disease mechanism and mechanism research in the industry and large-scale compound screening application, but also can be combined with a reprogramming technology to be applied to personalized precise medical treatment of patients.
Owner:PHARMARON BEIJING CO LTD

Method for treating diabetes mellitus based on traditional Chinese medicine acupoint injection viscera awakening therapy

PendingCN121796223ARestore the balance of yin and yang in the organsrestore islet functionAcupunctureInfusion syringesRegimenPancreatic hormone
The invention discloses a method for treating diabetes mellitus based on traditional Chinese medicine acupoint injection viscera awakening therapy, and relates to the technical field of traditional Chinese medicine. 3ml of medicine is injected into each acupoint of 0.9 N. S, and the amount of the medicine is reduced to 1.5-2ml for children; 2, one time every two days, ten times as a course of treatment, a second course of treatment is injected every 7-10 days, three courses of treatment are continuously used, in the step 1, I can reduce the dosage of insulin, II can also reduce the amount of hypoglycemic drugs, the amount of hypoglycemic drugs can be reduced in the second course of treatment for patients with general curative effects, and in the step 2, 20% of patients with three courses of treatment can be stopped. And the acupoint target injection therapy is adopted to dredge the channels and collaterals to viscera and reach the stomach, the liver, the pancreas and the spleen, so that the balance of yin and yang of the viscera is recovered, the pancreas islet function is gradually recovered, and finally the function of the viscera is recovered.
Owner:XIAN HUAYANTANG MEDICAL TECH CO LTD

Kit and system for detecting pancreatic islet function of subject

PendingCN121324654AMaterial analysis by optical meansSensorsReceptor activationPancreas
The invention relates to a kit and a system for detecting pancreatic islet function of a subject. The kit comprises a plurality of small chambers for containing different concentrations of an HCAR2 receptor activator or an HCAR3 receptor activator or an ester aqueous solution thereof. The kit provided by the invention can be used for effectively detecting the pancreatic islet function of a subject by evaluating the sensitivity degree of the subject to the HDAR2 receptor activator or the HDAR3 receptor activator or the ester thereof. The system disclosed by the invention can be used for quickly obtaining a detection result through several simple steps of operation in a short time, realizes multi-scene real-time detection in wards, physical examination centers, homes and the like, and is an objective, convenient and effective biological detection means for detecting the pancreas islet function of a subject.
Owner:SHANGHAI TIANYIN BIOTECH CO LTD